Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles. - Université de Tours Accéder directement au contenu
Article Dans Une Revue Journal of Controlled Release Année : 2013

Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles.

Emilie Allard-Vannier
Emilie Munnier
Martin Soucé
Igor Chourpa

Résumé

Hybrid (organic/inorganic) nanoparticles emerged as a simple solution to build "theranostic" systems. Due to their physical properties, superparamagnetic iron oxide nanoparticles (SPIONs) and plasmonic gold nanoparticles (Au-NPs) are extensively studied as a part of diagnostic and therapeutic strategies in cancer treatments. They can be used as agents for in vitro or in vivo imaging, for magnetic drug targeting and/or thermal therapy. Their functionalization with organic shells enhances their potential performance in tumor targeting and drug delivery. The advances in such hybrid nanocarriers are well illustrated with the example of the anticancer drug doxorubicin (DOX). The aim of this review is to give a multidisciplinary overview of such smart nanosystems loaded with DOX, based on examples taken from recent publications. From a physico-chemical point of view, we discuss the choices for the strategies for loading DOX and the consequences on drug release. From a biological point of view, we analyze the in vitro and in vivo assays concerning tumor imaging, targeted drug delivery and anticancer efficiency. Future opportunities and challenges are also addressed.

Dates et versions

hal-01128585 , version 1 (10-03-2015)

Identifiants

Citer

Juliette Gautier, Emilie Allard-Vannier, Emilie Munnier, Martin Soucé, Igor Chourpa. Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles.. Journal of Controlled Release, 2013, 169 (1-2), pp.48-61. ⟨10.1016/j.jconrel.2013.03.018⟩. ⟨hal-01128585⟩

Collections

UNIV-TOURS
57 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More